The EuroSIDA study is a prospective observational cohort study of more than 22000 patients followed in 107 hospitals in 35 European countries plus Israel and Argentina (see the EuroSIDA study group here). The main objective of the study is to follow the long-term clinical prognosis for the general population of HIV-infected patients living in Europe and to assess the impact of antiretroviral drugs on the long-term prognosis for these patients. The EuroSIDA study was initiated in 1994 and continues to expand in multiple ways. Being an observational study, the type of data collected has diversified tremendously since the start, as advances in the medical management of HIV has allowed for HIV-infected patients to foresee a good life prognosis. Early in the study, EuroSIDA initiated a focus on reliably collecting data on end-organ diseases and non-AIDS cancers, and confounders relevant for predicting risk factors for their occurrence. Much of the work relating to predicting the risk of cardiovascular disease (including the design of the D:A:D study) was a result of this foresight. Subsequently, the study has expanded the scope of research focus to also address liver disease, renal disease, and non-AIDS defining cancers.
For more information about the EuroSIDA Study, please contact the Coordinating Centre at: firstname.lastname@example.org
Primary funding for EuroSIDA is provided by the European Union’s Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement n˚ 260694. Current support also includes unrestricted grants by Bristol-Myers Squibb, Gilead, GlaxoSmithKline LLC, Janssen R&D, Merck and Co. Inc., Pfizer Inc. The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). Study supported by grant [grant number DNRF126] from the Danish National Research Foundation.
EuroSIDA countries and regions:
For a full list of EuroSIDA sites and countries, please see the EuroSIDA study group